Moore, Kathleen N <br/><br/>
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2017 
 - 1112-1118 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2016.69.9538  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Diarrhea--chemically induced<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm<br/>Fallopian Tube Neoplasms--chemistry<br/>Fatigue--chemically induced<br/>Female<br/>Folate Receptor 1--analysis<br/>Humans<br/>Hypotension--chemically induced<br/>Immunoconjugates--adverse effects<br/>Maytansine--adverse effects<br/>Middle Aged<br/>Nausea--chemically induced<br/>Ovarian Neoplasms--chemistry<br/>Peritoneal Neoplasms--chemistry<br/>Platinum Compounds--therapeutic use<br/>Response Evaluation Criteria in Solid Tumors<br/>Retreatment<br/>Vision Disorders--chemically induced